Benzinga | Dec 10, 2020 06:42AM EST

Goldman Sachs Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $24

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy rating and announces Price Target of $24.